Combined perioperative plasma endoglin and VEGF-A assessment in colorectal cancer patients

Folia Histochemica et Cytobiologica

Volumn 46, Issue 4, 2008, Pages 487-492

  Myśliwiec, Piotr ^a   Pawlak, Krystyna ^a   Kukliński, Adam ^a   Kedra, Boguslaw ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Angiogenesis; Colorectal cancer; Endoglin; VEGF A

Indexed keywords

CA 19-9 ANTIGEN; ENDOGLIN; TUMOR MARKER; VASCULOTROPIN A; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; BLOOD; CASE CONTROL STUDY; COLORECTAL TUMOR; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 60549089043     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-008-0066-8     Document Type: Article

References (34)

1. Saunders M, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer. 2006;95:131-138.
2. Hurwitz H, Kabbinavar F. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology. 2005;69 Suppl 3:17-24.
3. Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D. Systemic treatment of colorectal cancer. Eur J Cancer. 2002; 38:1000-1015.
4. Folkman J. Tumor angiogenesis and tissue factor. Nat Med. 1996;2:167-168.
5. Hanrahan V, Currie M, Gunningham S, Morrin H, Scott P, Robinson B et al. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol. 2003;200:183-194.
6. Stoeltzing O, Liu W, Reinmuth N, Parikh A, Ahmad SA, Jung YD et al. Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann Surg Oncol. 2003;10:722-733.
7. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol. 2004;17:197-203.
8. Broll R, Erdmann H, Duchrow M, Oevermann E, Schwandner O, Markert U et al. Vascular endothelial growth factor (VEGF) - a valuable serum tumour marker in patients with colorectal cancer? Eur J Surg Oncol. 2001;27:37-42.
9. Sun XF, Zhang H. Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas. Mol Cancer. 2006;5:43.
10. Akagi K, Ikeda Y, Sumiyoshi Y, Kimura Y, Kinoshita J, Miyazaki M et al. Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery. 2002;131:S109-113.
11. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992;267:19027-19030.
12. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. Faseb J. 2003;17:984-992.
13. Maio M, Altomonte M, Fonsatti E. Is it the primetime for endoglin (CD105) in the clinical setting? Cardiovasc Res. 2006;69:781-783.
14. Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med. 2004;2:18.
15. Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A et al. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer. 2003; 88:1424-1431.
16. Romani AA, Borghetti AF, Del Rio P, Sianesi M, Soliani P. The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count. J Surg Oncol. 2006;93:446-455.
17. Yu JX, Zhang XT, Liao YQ, Zhang QY, Chen H, Lin M et al. Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance. World J Gastroenterol. 2003;9:2866-2869.
18. Calabro L, Fonsatti E, Bellomo G, Alonci A, Colizzi F, Sigalotti L et al. Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol. 2003;194:171-175.
19. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001;7:524-532.
20. George ML, Dzik-Jurasz AS, Padhani AR, Brown G, Tait DM, Eccles SA et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg. 2001;88:1628-1636.
21. Messersmith W, Laheru D, Hidalgo M. Recent advances in the pharmacological treatment of colorectal cancer. Expert Opin Investig Drugs. 2003;12:423-434.
22. George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia. 2001;3:420-427.
23. Chin KF, Greenman J, Reusch P, Gardiner E, Marme D, Monson JR. Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer: associations with disease recurrence. Eur J Surg Oncol. 2003;29:497-505.
24. Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest. 2002;62:343-350.
25. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factorbeta pathways. J Biol Chem. 2002;277:43799-43808.
26. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. The Faseb Journal: Official Publication of the Federation of American Societies For Experimental Biology. 2000;14:55-64.
27. Jerkic M, Rodriguez-Barbero A, Prieto M, Toporsian M, Pericacho M, Rivas-Elena JV et al. Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovasc Res. 2006;69:845-854.
28. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG et al. Defective angiogenesis in mice lacking endoglin. Science. 1999;284:1534-1537.
29. Li C, Guo B, Wilson P, Stewart A, Byrne G, Bundred N et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer. 2000;89:122-126.
30. McCarthy M. Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet. 2003;361:1959.
31. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350:2335-2342.
32. Maharaj AS, D'Amore PA. Roles for VEGF in the adult. Microvasc Res. 2007;74:100-113.
33. Seon BK, Takahashi N, Haba A, Matsuno F, Haruta Y, She XW et al. Angiogenesis and metastasis marker of human tumors. Rinsho Byori. the Japanese Journal of Clinical Pathology. 2001;49:1005-1013.
34. Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol. 2007;170:1-15.